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64Cu-cyclam-RAFT-c(-RGDfK-)4, an aVb3 integrin-targeting tetrameric cyclic RGD peptide probe, is a
potential theranostic compound for positron emission tomography (PET) of tumor angiogenesis and for
internal radiotherapy owing to the multiple decay modes of 64Cu. Since kidneys are dose-limiting organs
in internal radiotherapy, we aimed to reduce the renal accumulation of 64Cu-cyclam-RAFT-c(-RGDfK-)4
by co-injection with Gelofusine (GF), a succinylated gelatin solution, and/or L-lysine (Lys), and to explore,
for the ﬁrst time, the related mechanisms using the noninvasive and quantitative PET imaging technol-
ogy. Biodistribution assays, dynamic and static PET scans, and metabolism studies with radio-thin-layer
chromatography (radio-TLC) were performed in healthy or aVb3-positive tumor-bearing mice. In the
results, co-injection with GF markedly reduced the renal uptake and slightly increased the tumor uptake
of 64Cu-cyclam-RAFT-c(-RGDfK-)4. L-Lysine alone had no effect on the probe biodistribution, but the
combined use of Lys and GF tended to enhance the effect of GF. Dynamic PET and metabolite analysis
by radio-TLC highly revealed that GF blocks the renal reabsorption of 64Cu-cyclam-RAFT-c(-RGDfK-)4,
but does not interfere with its metabolism and excretion. In conclusion, administration of GF and Lys
is a useful strategy for kidney protection in 64Cu-cyclam-RAFT-c(-RGDfK-)4-based internal radiotherapy.
 2013 The Authors. Published by Elsevier B.V.Open access under CC BY license. 1. IntroductionaVb3 Integrin, a transmembrane glycoprotein receptor highly
expressed on the surface of activated endothelial cells during angi-
ogenesis as well as on some types of tumor cells, is one of the key
biomarkers for tumor angiogenesis and plays important roles in
tumor growth, invasion, metastasis, and angiogenesis [1–3]. By
using a Regioselectively Addressable Functionalized Template
(RAFT) cyclodecapeptide scaffold (Fig. 1), we have previously
developed a cRGD (cyclic pentapeptide containing the tripeptide
sequence Arg-Gly-Asp) probe encompassing (1) the aVb3-targeting
domain, a cluster of 4 copies of a cyclo(-RGDfK-) monomer and (2)
a bifunctional chelator 1,4,8,11-tetraazacyclotetradecane (cyclam)
for 64Cu radiolabeling. This compound was referred to as 64Cu-
cyclam-RAFT-c(-RGDfK-)4 [4–6]. 64Cu (t1/2 12.7 h) is a promising
radionuclide with multiple decay modes—b+ (17.8%) used for
positron emission tomography (PET) [7] and b (38.4%) and Auger
electron (43%) used for internal radiation therapy [8]. Our recent
study demonstrated that 64Cu-cyclam-RAFT-c(-RGDfK-)4 PET
enables clear visualization of tumor angiogenesis and aids in
Fig. 1. Molecular structure of cyclam-RAFT-c(-RGDfK-)4.
Z.-H. Jin et al. / European Journal of Pharmaceutics and Biopharmaceutics 86 (2014) 478–486 479monitoring the effectiveness of antiangiogenic therapy in a mouse
model [9]. Subsequently, we plan to investigate the therapeutic po-
tential of this compound for internal radiation cancer therapy, also
known as peptide receptor radionucleotide therapy (PRRT) [10]. It
is important to note that 64Cu-cyclam-RAFT-c(-RGDfK-)4-based
PRRT would be used in diverse solid tumor types because it targets
not only aVb3-positive tumor cells but also aVb3-overexpressed
neoendothelial cells during angiogenesis, a key event required for
tumor growth. However, 64Cu-cyclam-RAFT-c(-RGDfK-)4 was pre-
dominantly excreted through the kidneys, with more than half of
the injected radioactivity eliminated within 1 h after injection
and a signiﬁcant amount of radioactivity being retained in the kid-
neys in an aVb3-nonspeciﬁc manner even 24 h after injection [6].
Because the kidney is the principal dose-limiting organ in internal
radiotherapy with radiolabeled peptides [11], reducing the renal
accumulation of 64Cu-cyclam-RAFT-c(-RGDfK-)4 is an essential
step before examining its treatment potential.
In general, peptides are ﬁltered through the glomerulus and are
subsequently reabsorbed by the proximal tubular cells [11]. Infu-
sion of the amino acids lysine and arginine has been reported to
reduce renal tubular reabsorption of the radiolabeled somatostatin
analogs pentetreotide or octreotide in animals and humans
[12–14]. It was hypothesized that the positively charged lysine or
arginine may competitively block the binding between a peptide
containing positively charged groups and a negatively charged site
on the tubular cell surface. Infusion of 25 g each of L-lysine (Lys)
and L-arginine, which was found to be both effective and safe, is
used as a standard procedure for kidney protection during PRRT
with radiolabeled somatostatin analogs [15].
Gelofusine (GF), a succinylated gelatin solution, is a widely used
plasma expander for patients suffering from massive hemorrhage,
severe trauma, or dehydration. ten Dam et al. reported that infu-
sions of low doses of GF in healthy male subjects resulted in
urinary excretion of low-molecular-weight protein b2-microglobu-
lin, suggesting that such an effect was most likely due to compet-
itive inhibition of tubular protein reabsorption [16]. van Eerd et al.
and Vegt et al. hypothesized that speciﬁc components in GF may
attenuate the tubular reabsorption process. Subsequent studies
on rats and mice showed that GF signiﬁcantly reduced the renal
uptake of 111In-octreotide as effectively as lysine did [17], and
studies on healthy volunteers showed that relatively small
amounts of GF (<420 mL) could effectively reduce the renal uptake
of 111In-octreotide [18].
Regarding RAFT-c(-RGDfK-)4, Briat et al. recently reported that
GF induced >50% reduction in the renal accumulation of
111In-labeled DOTA-RAFT-c(-RGDfK-)4 in mice [19]. Renal uptakeand retention of radiopharmaceuticals are dependent not only on
the characteristics of the targeting molecule, but also on the type
of radionuclide and chelating agent used. We observed that the
renal uptake levels of 111In-DOTA-RAFT-c(-RGDfK-)4 and 64Cu-
cyclam-RAFT-c(-RGDfK-)4 were substantially different, with bio-
distributions at 24 h after injection of 40%ID/g and 10%ID/g,
respectively [6,19]. Therefore, in this study, we determined the
effect of GF on the renal uptake and retention of 64Cu-cyclam-
RAFT-c(-RGDfK-)4 in normal and tumor-bearing mice. In compari-
son with the published work on the 111In-labeled analog, the
present study particularly evaluated (1) the dose–effect relation-
ship of GF, (2) the combined effect of GF and Lys, (3) the spatiotem-
poral changes in renal radioactivity caused by GF in the presence or
absence of Lys (GF ± Lys), and (4) the inﬂuence of GF ± Lys on the
metabolism of 64Cu-cyclam-RAFT-c(-RGDfK-)4. Another novelty is
that the present study explored the mechanisms underlying the
action of GF and Lys using the noninvasive and quantitative PET
imaging technology.2. Materials and methods
2.1. Cyclam-RAFT-c(-RGDfK-)4 and
64Cu radiolabeling
Cyclam-RAFT-c(-RGDfK-)4 (MW 4119.6) was synthesized as
reported previously [5], and radiolabeled with 64Cu in accordance
with our previous report [6] with minor modiﬁcations. In brief,
0.08 mM cyclam-RAFT-c(-RGDfK-)4 in dimethyl sulfoxide and
1.48 MBq/lL 64CuCl2 in ammonium citrate buffer (100 mM, pH
5.5) were mixed in a ratio of 1:1 (v/v) and incubated at 37 C for
1 h. The radiolabeling efﬁciency, as determined by reversed phase
(RP) high-performance liquid chromatography, was >98%, and the
speciﬁc radioactivity was 18.5 MBq/nmol.
2.2. GF and Lys solutions
Gelofusine (Braun Medical, Oss, Netherlands), kindly provided
by Dr. Lucie Sancey (University of Lyon 1, France), consists of a
40 g/L solution of succinylated gelatin for intravenous infusion,
and was diluted in normal saline (NS) for use in the present study.
L-Lysine (Sigma–Aldrich, Buchs, Switzerland) was dissolved in NS
and added to the injectate prior to administration.
2.3. Cell culture, animal, and tumor model
Human glioblastoma U87MG cells naturally expressing aVb3
were cultured as previously described [6]. Animal procedures were
approved by Institutional Animal Care and Use Committee of the
National Institute of Radiological Sciences (NIRS; Chiba, Japan).
Normal or tumor-bearing mice (female BALB/cAJcl-nu/nu; CLEA
Japan, Inc., Tokyo, Japan) at 7–8 weeks of age were examined.
The tumors, 7–10 mm in diameter, were developed by subcutane-
ous (s.c.) injection of 1  107 cells into the left shoulder region of
the mice.
2.4. Biodistribution studies
Mice were injected via tail vein (i.v.) with 0.74 MBq 64Cu-
cyclam-RAFT-c(-RGDfK-)4 with or without co-injection of GF, Lys,
or both (GF + Lys). The biodistribution study consists of the
following 3 sequential experiments. Experiments 1 (n = 3–4/group)
and 2 (n = 5/group) were designed to investigate the dose–effect
relation of GF (at 80, 120, and 200 mg/kg) and the combinatorial
effect of GF (80 mg/kg) and Lys (400 mg/kg) using normal mice.
Experiment 3 (n = 5–7/group) was performed to determine whether
GF or GF + Lys could affect the speciﬁc tumor uptake of
Table 1
Biodistribution of 64Cu-cyclam-RAFT-c(-RGDfK-)4 in normal mice with or without co-
injection of GF at various doses.
Organ Control GF
80 mg/kg 120 mg/kg 200 mg/kg
Blood 0.03 ± 0.01 0.05 ± 0.01 0.04 ± 0.01 0.05 ± 0.01
Heart 0.63 ± 0.17 0.90 ± 0.05a 0.84 ± 0.08 0.82 ± 0.07
Lung 1.28 ± 0.33 1.85 ± 0.11a 1.88 ± 0.06a 1.78 ± 0.26
Liver 4.13 ± 1.08 5.30 ± 0.15 4.75 ± 0.39 5.78 ± 0.77a
Pancreas 0.44 ± 0.10 0.57 ± 0.05 0.53 ± 0.02 0.57 ± 0.06
Spleen 1.69 ± 0.33 2.48 ± 0.23 2.23 ± 0.19 2.55 ± 0.58
Stomach 1.30 ± 0.41 1.71 ± 0.39 1.42 ± 0.35 1.77 ± 0.55
Intestine 1.44 ± 0.30 1.87 ± 0.07 1.58 ± 0.18 1.88 ± 0.30
Kidney 17.3 ± 3.71 11.2 ± 0.93b 10.6 ± 1.18b 10.7 ± 0.87b
Skin 1.68 ± 0.49 2.25 ± 0.25 1.79 ± 0.26 1.97 ± 0.37
Muscle 0.39 ± 0.11 0.59 ± 0.07 0.53 ± 0.02 0.66 ± 0.19
Bone 1.00 ± 0.23 1.30 ± 0.12 1.38 ± 0.52 1.33 ± 0.19
Tissue radioactivity was assessed at 3 h p.i. and is expressed as %ID/g (mean ± SD).
n = 3–4.
a P < 0.05 vs. Control (mice that received probe alone).
b P < 0.01 vs. Control (mice that received probe alone).
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kidneys, using tumor-bearing mice. It should be noted that
throughout this study, each injectate was adjusted to a 0.2 mL
volume with NS to avoid any possible effect due to the injected
volume. At 3 and/or 24 h post-injection (p.i.), the mice were sacri-
ﬁced and their blood was drawn. The kidney, tumor, and other
major organs of interest were dissected and weighed, and the
radioactivity was measured using a gamma counter with decay
correction. Radioactivity concentration was expressed as a per-
centage of the injected dose per gram of tissue (%ID/g) normalized
to a body weight of 20 g.
2.5. PET imaging and quantiﬁcation
Tumor-bearing mice (n = 4/group) received an i.v. injection of
18.5 MBq 64Cu-cyclam-RAFT-c(-RGDfK-)4 with or without co-
injection of 80 mg/kg GF ± 400 mg/kg Lys. Using a small-animal
PET system (Inveon; Siemens Medical Solutions USA, Inc., Mal-
vern, PA), dynamic PET imaging for a duration of 60 min (12 scans
of 5 min each) was performed immediately p.i., followed by 30-
min static imaging at 3.5 and 24 h p.i. During scanning, the mice
in prone position were anaesthetized with 1–1.5% isoﬂurane,
while maintaining normal body temperature. Images were recon-
structed using a 3D maximum a posteriori (MAP) method (18 iter-
ations with 16 subsets; b = 0.2) without attenuation correction.
Image analysis was performed using the ASIPro VM™ Micro PET
Analysis software (Siemens Medical Solutions, USA, Inc.). The
total injected dose was calculated by decay correction of total
activity present at the time of injection (t = 0). For radioactivity
quantiﬁcation in the tumor, both kidneys, and urinary bladder, re-
gions of interest (ROIs) encompassing the whole tissue area on
each of coronal slices were drawn manually, and all ROIs were
linked to form a 3D volume of interest (VOI) using the 3D (VOI)
dimensionality tool. For each VOI, the percentage of the total in-
jected dose (%ID) was calculated to represent the total activity
accumulation in the urinary bladder and both kidneys and the
mean %ID/g to represent tumor uptake, assuming a tissue density
of 1 g/mL. To quantify the radioactivity in the renal cortex, ROIs
encompassing the cortex were drawn from 3 coronal slices, the
mean %ID/g of each slice was recorded, and the average value
of mean %ID/g from the 3 slices was calculated. To estimate the
radioactivity in the blood pool, a ROI with a ﬁxed size of
0.1 cm2 was placed over the heart, and the blood radioactivity
was quantiﬁed as the mean %ID/g.
2.6. Metabolite analysis by radio-TLC
Normal mice (n = 3/group) were treated with the same injec-
tion schedule as in the aforementioned PET study. At 1 and
24 h p.i., the mice were sacriﬁced and urine, blood, kidney, and
liver were sampled. Blood samples were immediately subjected
to centrifugation at 2300g for 15 min at 4 C, and the plasma
supernatants were collected. Liver and kidney samples were
homogenized in ice-cold phosphate-buffered saline supplemented
with protease inhibitor cocktail (1:30 dilution; Sigma–Aldrich, St.
Louis, MO, USA). After centrifugation at 9100g for 30 min at 4 C,
the supernatants were collected. The extraction efﬁciency was
approximately 80% for kidney and liver samples, and >90% for
blood samples.
Partisil RP TLC plate (KC-18 Silica Gel 60 Å; Whatman Inc.,
Clifton, NJ, USA) as the stationary phase was loaded with
2–2.5 lL of plasma, urine, tissue supernatant, injectate, and undi-
luted 64Cu-cyclam-RAFT-c(-RGDfK-)4 or 64Cu solution, and
developed in the mobile phase of methanol/10% ammonium
acetate (70/30 v/v). The radioactive components separated
on the plate—corresponding to 64Cu-cyclam-RAFT-c(-RGDfK-)4, itsradioactive metabolites, and free 64Cu—were exposed to an imag-
ing plate, and scanned using a bioimaging analyzer as previously
described [6]. The proteins were then visualized by exposure to io-
dine vapor. Samples from the same mouse and the injectate as the
internal standard were analyzed on one TLC plate, with several
samples, including urine and the injectate, being appropriately di-
luted in NS.2.7. Statistical analysis
Quantitative data were presented as mean ± SD and
compared using one-way ANOVA followed by Bonferroni test for
multiple comparisons. P values < 0.05 were considered statistically
signiﬁcant.3. Results
3.1. Biodistribution studies
Table 1 shows the effect of various doses of GF on the biodistri-
bution of 64Cu-cyclam-RAFT-c(-RGDfK-)4 in normal mice at 3 h p.i.
Renal radioactivity was signiﬁcantly reduced by 35.3% in the pres-
ence of 80 mg/kg GF; however, increased doses of 120 and 200 mg/
kg did not lead to further reductions. Blood radioactivity (as low as
0.03 ± 0.01%ID/g) was not signiﬁcantly inﬂuenced by GF at any of
the doses tested. In other organs, co-injection with GF tended to re-
sult in a slight increase in radioactivity, independent of the doses
used. Based on these results, the dose of 80 mg/kg was selected
for all subsequent studies.
Fig. 2 shows the effect of Lys and the combined effect of GF
and Lys on the biodistribution of 64Cu-cyclam-RAFT-c(-RGDfK-)4
in normal mice at 3 and 24 h p.i. L-lysine alone did not affect
the biodistribution of 64Cu-cyclam-RAFT-c(-RGDfK-)4 at either 3
or 24 h p.i in any of the organs examined, except in the stomach.
When Lys was added to GF, the 31.5% (3 h p.i.) and 26.6%
reductions (24 h p.i.) in renal radioactivity caused by GF alone
were increased to 36.1% (P > 0.05) and 37.9% reductions
(P = 0.03), respectively. Interestingly, unlike GF alone, GF + Lys
did not signiﬁcantly affect accumulation of radioactivity in other
organs.
The effect of GF ± Lys was examined in mice bearing aVb3-
positive U87MG tumors (Table 2). The tumor uptake of 64Cu-
cyclam-RAFT-c(-RGDfK-)4 was slightly increased in the presence
of GF ± Lys. After co-injection with GF alone, the tumor-to-kidney
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Fig. 2. Biodistribution of 64Cu-cyclam-RAFT-c(-RGDfK-)4 in normal mice at 3 h (A) and 24 h (B) p.i. of 64Cu-cyclam-RAFT-c(-RGDfK-)4 alone (control) or with co-injection of
GF, Lys, or GF + Lys. n = 5; a,b,c,d P < 0.05, 0.01, 0.001, and 0.0001, respectively vs. control (i.e. the group of mice receiving probe alone); e P < 0.05 vs. GF group.
Table 2
Biodistribution of 64Cu-cyclam-RAFT-c(-RGDfK-)4 in U87MG tumor-bearing mice with or without co-injection of GF ± Lys.
Organ 3 h p.i. 24 h p.i.
Control GF GF + Lys Control GF GF + Lys
Blood 0.06 ± 0.01 0.08 ± 0.01 0.08 ± 0.01 0.06 ± 0.02 0.06 ± 0.01 0.06 ± 0.01
Liver 4.50 ± 0.77 5.84 ± 0.34a 5.94 ± 0.25a 3.30 ± 0.27 3.87 ± 0.54 3.48 ± 0.34
Kidney 19.9 ± 3.52 13.1 ± 0.76b 13.6 ± 0.40b 14.7 ± 1.06 10.31 ± 1.00c 9.47 ± 0.57c
Muscle 0.36 ± 0.05 0.43 ± 0.09 0.42 ± 0.04 0.27 ± 0.03 0.32 ± 0.07 0.29 ± 0.08
Tumor 6.95 ± 1.59 8.19 ± 1.28 9.26 ± 1.36 4.40 ± 0.70 5.39 ± 0.94 5.22 ± 1.08
T/K 0.35 ± 0.06 0.63 ± 0.10b 0.68 ± 0.09b 0.30 ± 0.05 0.53 ± 0.094a 0.56 ± 0.13a
T/M 19.4 ± 3.71 19.7 ± 4.14 22.5 ± 4.21 16.0 ± 1.71 17.2 ± 3.51 19.4 ± 6.93
Tissue radioactivity was assessed at 3 and 24 h p.i. and is expressed as %ID/g (mean ± SD). T/K: tumor-to-kidney ratio; T/M: tumor-to-muscle ratio. n = 5–7.
a P < 0.01 vs. Control (mice that received probe alone).
b P < 0.001 vs. Control (mice that received probe alone).
c P < 0.0001 vs. Control (mice that received probe alone).
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76.7% (P = 0.005) at 3 and 24 h p.i., respectively. Similarly, with
GF + Lys, the tumor-to-kidney uptake ratios were signiﬁcantly
increased by 94.3% (P = 0.0002) and 86.7% (P = 0.0018) at 3 and24 h p.i., respectively. However, no statistical signiﬁcance was
observed between the GF alone and GF + Lys groups. Further, the
tumor-to-muscle uptake ratios were not signiﬁcantly affected by
co-injection with GF ± Lys.
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Fig. 3. Representative coronal PET images of U87MG tumor-bearing mice administered with 64Cu-cyclam-RAFT-c(-RGDfK-)4 alone (A) or with co-injection of GF (B) or
GF + Lys (C). Dynamic imaging was performed 5 min (0) for each scan from 0 up to 600 p.i., and static images were acquired at 3.5 and 24 h p.i. Arrows in A, B, and C depict both
kidneys. D, E, and F are zoomed (4.5) images of kidneys delineated in dotted square in A, B, and C, respectively.
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Fig. 4. A set of coronal sections of PET images derived from the same set of mice
described in Fig. 2. Tumor (arrow) uptake of 64Cu-cyclam-RAFT-c(-RGDfK-)4 is
clearly visible.
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Fig. 3 shows the optimum coronal sections for both kidneys
from the representative PET images of U87MG tumor-bearing
mice. These images were derived from a 1-h dynamic scan and sta-
tic scans at 3.5 and 24 h p.i. of 64Cu-cyclam-RAFT-c(-RGDfK-)4
alone (control) or with co-injection of GF ± Lys, allowing improved
visualization of the spatiotemporal distribution of renal radioactiv-
ity. In the control mouse, the radioactivity levels in both kidneys
indicated rapid uptake within 0–5 min p.i., fast washout until
15–20 min p.i., and signiﬁcant retention in the renal cortex at later
time points (Fig. 3A and D). When compared to the control mouse,
mice co-injected with either GF (Fig. 3B and E) or GF + Lys (Fig. 3C
and F) displayed differences in both the intensity and distribution
of renal radioactivity from 15–20 min p.i., with retention in the
renal cortex being lower than that in the renal pelvis (up to
35–40 min p.i.). Fig. 4 shows another set of coronal sections for
optimum visualization of the tumors. The kinetics of uptake,
washout, and retention of 64Cu-cyclam-RAFT-c(-RGDfK-)4 were ob-
served to be comparable among all of the tumors from the control
and GF ± Lys-administered mice, with this aVb3-positive tumor
clearly detected with high contrast against collateral tissue from
as early as 30 min up to 24 h p.i.
Quantitative analysis of dynamic PET images revealed a steady
increase in the amount of radioactivity accumulated in the urinary
bladders during the 60-min scanning period for all groups of mice,
reﬂecting cumulative urinary excretion of the injected radioactiv-
ity (Fig. 5A). Co-injection with GF ± Lys signiﬁcantly increased per-
centage urinary excretion, a quantity roughly corresponding to the
decreased percentage in total renal radioactivity. The value of area
under the time–activity curve (AUC) from 12.5 to 57.5 min p.i. was
2293 ± 39 for the control group, which was slightly increased to
2382 ± 111 and 2416 ± 78 for the GF and GF + Lys group, respec-
tively. Fig. 5B displays the kinetics of total renal radioactivity.
Co-injection with GF ± Lys tended to decrease renal radioactivity
after the initial uptake and washout of the probe within 12.5 min
p.i., resulting in signiﬁcantly lower radioactivity levels in retention.
AUC from 12.5 to 57.5 min p.i. was 210 ± 41.1 for the control group,
which was signiﬁcantly reduced to 152.4 ± 11.5 (P = 0.048) and
143.1 ± 21.3 (P = 0.022) for the GF and GF + Lys group, respectively.
Fig. 5C shows the blood time–activity curves. Co-injection withGF ± Lys did not affect the blood clearance pattern of 64Cu-
cyclam-RAFT-c(-RGDfK-)4.
Fig. 6A shows the time–activity curves for the renal cortex, the
main localization site of 64Cu-cyclam-RAFT-c(-RGDfK-)4 in the
kidneys, exhibiting similar kinetics pattern to the corresponding
time–activity curves for the whole kidney. Co-injection with
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Fig. 5. (A and B) Time course of accumulation of radioactivity in both kidneys and
the urinary bladder. (C) Clearance of radioactivity from blood pool over time. The
data were obtained by quantitative analysis of dynamic PET images of U87MG
tumor-bearing mice at 0–60 min p.i. of 64Cu-cyclam-RAFT-c(-RGDfK-)4 alone
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(empty triangle). The graph in A is enlarged in B with a smaller maximum value for
the Y-axis. n = 4; GF vs. Control: *P < 0.05; GF + Lys vs. Control: #P < 0.05.
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the renal cortex for a longer duration, i.e. from 27.5 min to 24 h
p.i., compared to the control injection. A 41.9%, 38.4%, and 31.9%
reduction was achieved by co-injection with GF alone at
57.5 min, 3.5 h, and 24 h p.i., respectively. Addition of Lys
enhanced the effect of GF, as shown by the slightly increasedreduction ratios of 45.2%, 43.1%, and 36.5% observed at 57.5 min,
3.5 h, and 24 h p.i., respectively. Tumor uptake increased in
GF ± Lys-administered mice compared to that in the control mice,
with statistical signiﬁcance observed for the GF alone group at
indicated time points (Fig. 6B).3.3. Radio-TLC metabolite analysis
Fig. 7 shows representative results of radio-TLC analysis of plas-
ma, urine, liver, and kidney samples from normal mice at 1 and
24 h p.i. of 64Cu-cyclam-RAFT-c(-RGDfK-)4 alone (control) or with
co-injection of GF ± Lys. Three independent experiments yielded
similar results. Iodine vapor staining revealed that the protein
components of plasma and tissue extracts remained at the origin
(data not shown). Except in the urine and plasma at 24 h p.i., one
or two closely overlapping spots were observed in all samples from
control mice at similar or nearby positions from the intact probe.
The urine sample at 1 h p.i. showed a spot matching with the intact
probe, whereas, at 24 h p.i., it showed an irregularly shaped spot
that migrated faster than the time required for detection of the in-
tact probe, indicating excretion of the mixture of radiolabeled
metabolites. At 24 h p.i., the plasma was barely detected because
of very low radioactivity. Co-injection with GF ± Lys was observed
to have no signiﬁcant effect on the metabolism of 64Cu-cyclam-
RAFT-c(-RGDfK-)4.4. Discussion
In recent years, there has been increasing interest in developing
radiolabeled peptides for cancer theranostics [20,21] because pep-
tides, in general, have many key advantages over proteins, such as
faster clearance from the blood and non-target tissues, more rapid
tissue penetration, lower immunogenicity, and easier and less
expensive production [10]. Further, reduction in renal retention
of radioactive metabolites is important for PRRT in order to avoid
potential nephrotoxic effects and widen the therapeutic windows
[11,20]. Therefore, based on the therapeutic potential of 64Cu-cy-
clam-RAFT-c(-RGDfK-)4, an efﬁcient strategy to reduce renal up-
take levels of this probe is required.
In the current study, we demonstrated that co-injection with GF
efﬁciently reduced the uptake of 64Cu-cyclam-RAFT-c(-RGDfK-)4 in
mouse kidneys by 30–40% (i.e. from 30 min to 24 h p.i.). Briat et al.
recently reported that either pre- (2–5 min before) or co-injection
with GF (200 mg/kg; 4 mg/mouse for a 20-g mouse) could reduce
the renal uptake of 111In- or ﬂuorescent dye-labeled RAFT-
c(-RGDfK-)4 in mice by >50% at 1 and 24 h p.i. [19]. The 2 studies
demonstrated that GF could primarily affect the behavior of the
peptide, with somewhat varied efﬁciency depending on the type
of conjugate used. Comparison of the biodistribution data obtained
for 111In- and 64Cu-labeled RAFT-c(-RGDfK-)4 at 24 h p.i. showed
that renal uptake for the former probe is far greater than that for
the latter (42.3 ± 9.3%ID/g vs. 14.4 ± 1.0%ID/g). This difference in
renal uptake may be caused by at least partially distinct mecha-
nisms involved in the renal uptake of the 2 probes. Here, we
examined a range of GF doses and demonstrated that 80 mg/kg
of GF was sufﬁcient to reduce the uptake of 64Cu-cyclam-RAFT-
c(-RGDfK-)4 in mouse kidney, and no further enhancement could
be achieved at higher doses. Melis et al. reported similar ﬁndings
with the 111In-labeled somatostatin analog octreotate in rats
[22]. In humans, one study showed that infusion of relatively small
amounts of GF (average of 12.9 g in less than 420 mL NS) can effec-
tively reduce the renal uptake of 111In-octreotide by 45% without
side effects [18].
The inﬂuence of GF on the uptake of 64Cu-cyclam-RAFT-c
(-RGDfK-)4 in other major organs and aVb3-positive tumors was
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ter the blood clearance rate of 64Cu-cyclam-RAFT-c(-RGDfK-)4. For
several other healthy organs, slight but signiﬁcant increases in
accumulation of radioactivity were observed in biodistribution
studies. Similarly, tumor uptake was also found to be slightly yet
signiﬁcantly enhanced in quantitative analysis of PET imaging
within 1 h p.i. In addition, the tumor-to-kidney uptake ratios were
found to be signiﬁcantly increased by 80% and 76.7% at 3 and 24 h
p.i., respectively, indicating that co-injection with GF could broad-
en the therapeutic window considerably. Our observation concern-
ing slightly increased tumor uptake is in accordance with the
results of Briat et al., who reported a 16.4% increase in tumor
uptake with GF co-injection [19]. The effect of GF on other organs
aside from the kidneys may relate to its volumetric effect as a
blood volume expander. Regarding the combined use of GF and
Lys, GF and Lys were reported to additively reduce the renal uptake
of 177Lu-octreotate and 111In-octreotide in rats [22,23]. However, in
the present study, the effects of Lys alone on the renal uptake of
64Cu-cyclam-RAFT-c(-RGDfK-)4 were not observed, and the com-
bined use of Lys and GF tended to enhance the efﬁciency of GF only
to a limited extent. In consideration of the liver uptake that was
found signiﬁcantly increased by GF alone but not GF + Lys
(Fig. 2), it might be even safer to use both of GF and Lys forco-injection with 64Cu-cyclam-RAFT-c(-RGDfK-)4 in internal
radiotherapy.
One important characteristic of the present study is that dy-
namic PET imaging was successfully used to directly analyze the
mechanism of how and when GF affected the renal accumulation
and elimination of 64Cu-cyclam-RAFT-c(-RGDfK-)4. During a 1-h
scan, we observed that GF primarily affected the phase between
the initial rapid washout of the peptide after renal uptake and
the ﬁnal retention of peptide. This process was presented as slow
decline in renal radioactivity (an indication of strong tubular reab-
sorption) in the absence of GF, which was replaced by relatively
faster decline of the radioactivity in the presence of GF, suggesting
impairment of tubular reabsorption. Dynamic PET images clearly
showed that radioactivity was predominantly found in the cortex
of the kidneys in control mice as early as 20–25 min p.i. and was
retained for long periods thereafter. In addition to reduced radioac-
tivity in the renal cortex, radioactivity in mice co-injected with GF
could be clearly visualized in the renal pelvic area even up to
35–40 min p.i., which is indicative of the active transit of the radio-
activity into the urinary bladder. Co-injection of GF resulted in
increase in urinary bladder radioactivity, which corresponded to
a decrease in total renal radioactivity, indicating that decreased
renal uptake was due to the blockade of renal reabsorption of
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Fig. 7. Radio-TLC analysis of the metabolites in blood, urine, liver, and kidney of
normal mice receiving 64Cu-cyclam-RAFT-c(-RGDfK-)4 alone (A and D) or with co-
injection of GF (B and E) or GF + Lys (C and F). A–C: at 1 h p.i. D–F: at 24 h p.i. G:
Standards. Lane 1 injectate, Lane 2 plasma, Lane 3 liver, Lane 4 kidney, Lane 5 urine,
Lane 6 64CuCl2, Lane 7 64Cu-cyclam-RAFT-c(-RGDfK-)4. Dotted lines the position of
standard probe; Arrows indicate the origin.
Z.-H. Jin et al. / European Journal of Pharmaceutics and Biopharmaceutics 86 (2014) 478–486 48564Cu-cyclam-RAFT-c(-RGDfK-)4, the predominant radioactive
component detected in the urine samples of mice with or without
co-injection of GF ± Lys at 1 h p.i. In addition, neither PET nor bio-
distribution studies showed the effect of GF on the blood clearance
of 64Cu-cyclam-RAFT-c(-RGDfK-)4, and in vivo metabolite analysis
did not reveal the effect of GF on the metabolism of 64Cu-
cyclam-RAFT-c(-RGDfK-)4. Taken together, these data strongly
suggest that co-injection with GF can result in reduced renal
accumulation of 64Cu-cyclam-RAFT-c(-RGDfK-)4, which is possibly
achieved through suppression of tubular reabsorption.
Megalin, a multiligand receptor expressed exclusively on the
apical membrane of proximal tubular cells, can bind to a variety
of structurally distinct proteins, peptides, drugs, and other mole-
cules [24–27]. Megalin-mediated endocytosis has been reported
to play a signiﬁcant role in the renal reabsorption of several radio-
labeled peptides irrespective of their molecular targets, molecular
weights, numbers of amino acid residues (AARs), or numbers of
charged AARs (CAARs) [24,26]. Based on these studies, we consider
that megalin may also be involved in the renal reabsorption of
64Cu-cyclam-RAFT-c(-RGDfK-)4. The number of CAARs in a radiola-
beled peptide has been shown to be related to its renal uptake
levels [26,28]. Gotthardt et al. reported a positive relationship
between the renal uptake levels of radiolabeled peptides and the
numbers of CAARs (Glu, Lys, Asp, or Arg) contained in the peptides
in the following order: exendin (10 CAARs) > minigastrin (7
CAARs) > octreotide (1 CAARs) > bombesin (0 CAARs) [28]. 64Cu-
cyclam-RAFT-c(-RGDfK-)4 contains 8 CAARs including 4 Arg
(positive charge) and 4 Asp (negative charge). The Lys residues
contained in this probe are capped and therefore have no charge.
Owing to the presence of 8 CAARs, the renal uptake of the probe
would increase substantially. The positively charged Lys was found
to reduce the renal uptake of the radiolabeled somatostatin
analogs pentetreotide, octreotide, and octreotide (containing a
single Lys residue each) through a putative competitive mecha-
nism [12–14,28]. In the present study, co-injection with Lys didnot reduce the renal uptake of 64Cu-cyclam-RAFT-c(-RGDfK-)4,
possibly because of the lack of charged Lys residues. In addition
to the number and type of CAARs, factors such as their structure
and distribution inside a molecule may also contribute to renal
reabsorption mechanisms. Unlike Lys, GF reduced the renal uptake
of all the radiolabeled peptides examined [19,26,28], including
64Cu-cyclam-RAFT-c(-RGDfK-)4 investigated in this study. This
could be because GF is a polypeptide-based succinylated gelatin
composed of several molecules of varying sizes and structures,
with both negative and positive CAARs; it may therefore possess
the ability to interact with several binding domains of megalin
simultaneously, thereby efﬁciently blocking the renal reabsorption
of various molecules.
Aside from co-injection with Lys and GF, other strategies have
been reported to reduce the renal uptake and retention of radiola-
beled peptides, especially somatostatin analogs [13,29–32]. In
addition to these, modiﬁcation of the peptide by coupling it with
another molecule (such as polyethylene glycol) can alter the phar-
macokinetics by increasing the size and hydrophilicity of the mol-
ecule and masking its charges [11], which may also be considered
in future studies for reducing the renal accumulation of 64Cu-cy-
clam-RAFT-c(-RGDfK-)4. In addition, our subsequent studies on
the development of 64Cu-cyclam-RAFT-c(-RGDfK-)4 internal radio-
therapy will also focus in estimating and determining the thera-
peutic but non-nephrotoxic doses of this radioactive compound.5. Conclusion
Co-injection with GF effectively reduced uptake of 64Cu-cyclam-
RAFT-c(-RGDfK-)4 in mouse kidney. L-lysine alone had no effect on
the probe biodistribution, but the combined use of Lys and GF
tended to enhance the effect of GF. Dynamic PET imaging enabled
visualization and quantiﬁcation of the spatiotemporal change in
renal radioactivity caused by GF and strongly suggested that the
mechanism of action of GF at least partially occurs via inhibition
of renal tubular reabsorption of 64Cu-cyclam-RAFT-c(-RGDfK-)4.
The use of GF should be included in future studies exploring the
therapeutic potential of 64Cu-cyclam-RAFT-c(-RGDfK-)4.
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